TB-500 vs thymosin beta-4: is it the same peptide?

The short answer: TB-500 and thymosin beta-4 are related but not the same. Thymosin beta-4 (often shortened to TB4 or Tβ4) is a natural protein that the body releases after injury. Doping laboratories that tested a product sold as TB-500 found that its key ingredient was a synthetic, acetylated copy of just 7 amino acids from thymosin beta-4, the segment known as LKKTETQ. [1] [2] Marketing for TB-500 does not always make clear which of the two molecules a product contains, so the label alone does not tell you what is inside.

The practical point: the human studies people cite for "TB-500" were done with full-length thymosin beta-4, not the fragment. No human trial of the TB-500 fragment has been published.

Is thymosin beta-4 the same as TB-500?

Thymosin beta-4 is a small protein made by many cell types. It binds actin, the protein that lets cells move and change shape, and after injury it is released by platelets and immune cells. It promotes cell migration and new blood vessel growth, reduces inflammation, and in animal models reduces scarring. [3]

The LKKTETQ segment at positions 17 to 23 is the active site responsible for actin binding, cell migration, and wound healing. [1] The equine doping study describes TB-500 as a veterinary preparation whose key ingredient is a synthetic version of that segment, with an acetyl group added to one end. [1] A Belgian doping laboratory confirmed the acetylated fragment in a TB-500 product and suggested a way to test for it in blood and urine. [2]

In short:

• Thymosin beta-4 (TB4): the full-length natural protein. It has phase 1 safety trials and phase 2 eye and wound trials in people, plus animal data in wound, heart, eye, and brain models.
• TB-500 (as analyzed): a synthetic acetylated 17 to 23 fragment. It has no published human trial, and its claimed effects are inferred from studies of the full protein.
• Both: not FDA approved, and both are named on the WADA list. [14]

TB4 vs TB-500: which has human evidence?

Full-length thymosin beta-4 has a small but real human record.

• Wound healing (animal): in rats, thymosin beta-4 increased wound reepithelialization by 42% at day 4 and up to 61% at day 7 versus saline. [4]
• Dry eye (human): a phase 2 trial of a thymosin beta-4 eye drop in 72 adults missed both primary endpoints, although several secondary measures improved. [5]
• Safety (human): two randomized, placebo-controlled phase 1 studies in healthy volunteers, the second using a recombinant form in China, gave intravenous thymosin beta-4 across a range of doses and reported only mild to moderate adverse events, with no serious events or dose-limiting toxicity. [6] [7]
• Skin ulcers (human): a review of two phase 2 trials in venous stasis and pressure ulcers reported faster healing, by almost a month, in patients who healed. [8]

None of this was done with the TB-500 fragment, and none of it tested injections under the skin for muscle, tendon, or joint injuries. A 2026 review of peptides used in sports medicine concluded that rigorous human safety data for unapproved peptides such as TB-500 are scarce. [11] That is why our evidence grade for TB-500 is animal only. The wound healing page lists what does have human evidence.

TB-500 capsules, nasal spray, and TB-500 spray

The human thymosin beta-4 studies used eye drops, intravenous infusion, or a topical gel on wounds. [5] [6] [8] We found no published study of TB-500 or thymosin beta-4 taken as a capsule or nasal spray, in people or animals, and no data on whether either form is absorbed. The doping laboratory work measured the fragment in the blood and urine of horses after administration, not in people taking oral or nasal products. [1] Capsules and sprays are therefore untested on the most basic question: whether the peptide reaches the bloodstream at all.

Does thymosin beta-4 cause cancer?

No study has shown that taking thymosin beta-4 or TB-500 causes cancer in people. But there is a real theoretical concern, and it follows from how the protein works.

The same activities that help wounds heal, cell migration and new blood vessel growth, are also what tumors use to spread. In mouse and cell experiments, thymosin beta-4 was required for a gene program linked to metastasis, cancer cells lacking it spread less in mice, and high thymosin beta-4 expression was associated with poorer prognosis across several human cancer datasets. [9] In thyroid tissue, thymosin beta-4 was barely detectable in normal and benign samples but overexpressed in several thyroid cancers, and higher expression tracked with more advanced disease. [10]

These findings describe the body's own thymosin beta-4 inside tumors. They do not show that an injected product starts a cancer. They are a reason why people with a current or past cancer should raise any thymosin beta-4 product with their oncologist, and why the lack of long-term human safety data matters.

Why the difference matters

The TB4 vs TB-500 distinction is not a naming technicality. The two molecules differ in size, in how they are made, and in what has been studied. A claim drawn from the full-length protein, such as the phase 1 safety results, does not automatically apply to a 7 amino acid fragment, and the fragment has never had its own human safety study. [2] [6]

It also matters for testing. Doping laboratories built their detection methods around the acetylated fragment and its breakdown products, because that is what they found in the product. [1] For anyone weighing a claim about TB-500, the first question is which molecule the claim is actually about.

TB-500 with BPC-157 and other blends

TB-500 is most often sold alongside BPC-157, the combination covered on our Wolverine stack page. It also appears in the GLOW blend with GHK-Cu. No trial has tested TB-500 in combination with anything. Our BPC-157 vs TB-500 comparison shows that neither has a human trial for injury healing, and our thymosin alpha-1 vs TB-500 comparison explains how two peptides with "thymosin" in their names differ in both biology and evidence.

Is TB-500 legal?

TB-500 is not an FDA approved drug. On July 23 to 24, 2026, FDA's Pharmacy Compounding Advisory Committee recommended adding it to the 503A bulks list. [12] Until FDA publishes a final rule, it is not on that list and a compounding pharmacy has no federal basis to make it from bulk. [13] Products sold for research use are not lawful for human use and are not verified for identity, which matters more than usual here, because the name covers two different molecules.

For athletes, WADA lists thymosin beta-4 and TB-500 by name under section S2, prohibited at all times. [14]

The TB-500 regulatory timeline tracks the rulemaking, and the TB-500 cost page explains why there is no lawful price to compare yet.